Metformin Found to Mimic Intense Exercise's Metabolic Benefits

Study shows diabetes drug increases molecule linked to appetite suppression and weight loss, even without physical activity

Apr. 11, 2026 at 9:54pm

Got story updates? Submit your updates here. ›

A highly detailed, translucent X-ray-style image showing the intricate internal structures of a human cell or organ, visualizing the molecular-level effects of metformin on the body's metabolism.An X-ray-like image reveals the intricate inner workings of a human cell, highlighting the potential of metformin to mimic the metabolic benefits of intense exercise.Sault Ste. Marie Today

Researchers at the University of Miami Miller School of Medicine have discovered that the diabetes drug metformin can mimic the metabolic benefits of intense exercise, even in sedentary individuals. The study, published in EMBO Molecular Medicine, found that metformin increased levels of the molecule N-lactoyl-phenylalanine (Lac-Phe), which spikes after intense physical activity and is associated with appetite suppression and weight loss.

Why it matters

This finding is significant because it suggests metformin could provide similar metabolic advantages as exercise, which is often challenging for cancer patients to achieve due to fatigue and treatment-related limitations. The discovery highlights metformin's potential to support metabolic health during cancer treatment, an important aspect for both patients and healthcare providers.

The details

The study focused on 29 men diagnosed with prostate cancer, analyzing the impact of metformin on Lac-Phe levels. Researchers found that the drug increased Lac-Phe even without any actual exercise, mimicking the molecular signals of intense physical activity. Lead author Dr. Marijo Bilusic, a medical oncologist, emphasized the clinical implications, stating the discovery could be particularly meaningful for patients whose treatments or symptoms restrict physical activity.

  • The study was published in the journal EMBO Molecular Medicine in 2026.

The players

Dr. Marijo Bilusic

A medical oncologist and lead author of the study.

David Lombard

A Sylvester researcher and professor of pathology and laboratory medicine.

University of Miami Miller School of Medicine

The institution where the research was conducted.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

What’s next

The research team's findings have sparked further interest in the potential of metformin as a cancer-fighting drug. Earlier studies have already linked metformin to a reduced risk of oesophageal cancer and suggested its potential in preventing prostate cancer.

The takeaway

This discovery doesn't introduce a new cancer biomarker but rather provides a clearer understanding of how metformin can support metabolic health during cancer treatment, an aspect that is crucial for both patients and healthcare providers.